Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099461 | 0.88 | TUBB1 (0.45) | HDAC8TUBB1KDM4EATMHDAC6 | |
| SCHEMBL7100378 | 0.83 | HDAC8 (0.42) | HDAC8KDM4EATMHDAC6HDAC2 | |
| SCHEMBL28762088 | 0.79 | HDAC8 (0.40) | HDAC8TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL6087582 | 0.79 | HDAC6 (0.38) | HDAC8HDAC6MAPK1RAB9AHDAC2 | |
| SCHEMBL27528600 | 0.78 | TUBB4A (0.47) | TUBB1TUBB4ATUBBTUBA3CCES1 | |
| SCHEMBL22909519 | 0.78 | TAS2R14 (0.48) | HDAC8HDAC6LMNAHDAC2KMT2A | |
| SCHEMBL29671306 | 0.78 | TAS2R14 (0.48) | HDAC8HDAC6LMNAHDAC2KMT2A | |
| SCHEMBL7535728 | 0.74 | TUBB1 (0.50) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL6086580 | 0.73 | TUBB1 (0.45) | TUBB1TUBB4ATUBBTUBA3CCES1 | |
| SCHEMBL30150631 | 0.73 | TUBB1 (0.45) | TUBB1TUBB4ATUBBTUBA3CCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253336-B | Compounds for the treatment of cancer | GTX公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-106794174-B | Compounds for the treatment of cancer | GTX公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10155728-B2 | Compounds for treatment of cancer | GTX INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-1206256-B8 | COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDE AND PLATIN COMPOUND | AMGEN INC (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1206256-B1 | COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDE AND PLATIN COMPOUND | TULARIK INC (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1206256-A2 | COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDE AND PLATIN COMPOUND | Tularik Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6355628-B1 | Such as 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene (batabulin) with antineoplastic platinum coordination complex such as cisplatin | TULARIK INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001008693-A2 | COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDE AND PLATIN COMPOUND | TULARIK INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155728-B2 | Compounds for treatment of cancer | TP53, TUBB1, TUBB6 | HDAC8 903/4885TUBB1 2/4885TUBB4A 7/4885 |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | HDAC8 903/4885TUBB1 2/4885TUBB4A 7/4885 |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | HDAC8 903/4885TUBB1 2/4885TUBB4A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.